MDT

96.47

-0.12%↓

136.94

-0.25%↓

VEEV

224.69

-0.21%↓

HQY

91.7

-0.66%↓

PHR.US

16.91

-0.18%↓

MDT

96.47

-0.12%↓

136.94

-0.25%↓

VEEV

224.69

-0.21%↓

HQY

91.7

-0.66%↓

PHR.US

16.91

-0.18%↓

MDT

96.47

-0.12%↓

136.94

-0.25%↓

VEEV

224.69

-0.21%↓

HQY

91.7

-0.66%↓

PHR.US

16.91

-0.18%↓

MDT

96.47

-0.12%↓

136.94

-0.25%↓

VEEV

224.69

-0.21%↓

HQY

91.7

-0.66%↓

PHR.US

16.91

-0.18%↓

MDT

96.47

-0.12%↓

136.94

-0.25%↓

VEEV

224.69

-0.21%↓

HQY

91.7

-0.66%↓

PHR.US

16.91

-0.18%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

0.98

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.95

Max

0.99

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+400% upside

Turustatistika
By TradingEconomics
Turukapital	-11M 115M
Eelmine avamishind	0.98
Eelmine sulgemishind	0.98

Uudiste sentiment

By Acuity

50%

151 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. dets 2025, 23:49 UTC

Omandamised, ülevõtmised, äriostud

WiseTech to Sell Expedient to Appease Competition Regulator

30. dets 2025, 17:12 UTC

Suurimad hinnamuutused turgudel

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

30. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. dets 2025, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

30. dets 2025, 21:08 UTC

Market Talk

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

30. dets 2025, 20:41 UTC

Market Talk

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

30. dets 2025, 20:37 UTC

Tulu

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

30. dets 2025, 19:29 UTC

Market Talk

Corn Extends Pullback in Light Trade -- Market Talk

30. dets 2025, 18:29 UTC

Market Talk

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

30. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. dets 2025, 16:20 UTC

Tulu

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

30. dets 2025, 16:18 UTC

Omandamised, ülevõtmised, äriostud

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

30. dets 2025, 16:10 UTC

Market Talk

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

30. dets 2025, 15:24 UTC

Market Talk

Australian Dollar Could Rise Versus Sterling -- Market Talk

30. dets 2025, 15:10 UTC

Omandamised, ülevõtmised, äriostud

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

30. dets 2025, 14:24 UTC

Omandamised, ülevõtmised, äriostud

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

30. dets 2025, 14:22 UTC

Omandamised, ülevõtmised, äriostud

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

30. dets 2025, 14:20 UTC

Omandamised, ülevõtmised, äriostud

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

30. dets 2025, 14:17 UTC

Omandamised, ülevõtmised, äriostud

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

30. dets 2025, 14:16 UTC

Omandamised, ülevõtmised, äriostud

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

30. dets 2025, 14:14 UTC

Omandamised, ülevõtmised, äriostud

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

30. dets 2025, 14:12 UTC

Omandamised, ülevõtmised, äriostud

LVMH: Les Editions Croque Futur Is a French Publishing House

30. dets 2025, 14:10 UTC

Omandamised, ülevõtmised, äriostud

LVMH Acquires Les Editions Croque Futur

30. dets 2025, 13:49 UTC

Omandamised, ülevõtmised, äriostud

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

30. dets 2025, 13:36 UTC

Market Talk

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

30. dets 2025, 13:30 UTC

Market Talk

Crude Futures Gain in Light Holiday Trade -- Market Talk

30. dets 2025, 12:55 UTC

Market Talk

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

30. dets 2025, 11:55 UTC

Market Talk

Tulu

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

30. dets 2025, 11:47 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

30. dets 2025, 11:35 UTC

Omandamised, ülevõtmised, äriostud

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

400% tõus

12 kuu keskmine prognoos

Keskmine 5 USD 400%

Kõrge 8 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

151 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.